Abionyx Pharma accelerates its development by launching a new biomanufacturing campaign based

24 mai 2023

ABIONYX Pharma is launching a new GMP biomanufacturing campaign for its ApoA-I therapy, financed by an equity-linked facility of up to €12 million subscribed by IRIS.

Toulouse, France May 23, 2023 – ABIONYX Pharma accelerates its development by launching a new biomanufacturing campaign based on the recently announced robust innovative process supported by an equity-linked financing facility

Download Abionyx press release